Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

There's no question about it, McDonald's is the most successful restaurant in the history of the world. The company isn't ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

NASDAQ tests resistance at 21,550 – 21,600 amid rising demand for tech stocks. Palantir Technologies, which is up by 23%, is ...

The Senate finance committee on Tuesday voted 14 to 13 in favour of his confirmation to run the Department of Health and ...

Robert F. Kennedy has been handed a tough job. He must restore people’s confidence in the public health system and change the conversation regarding healthcare from how we pay for ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...